Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009 Company Focused on Areas of High Medical Need Including Cancer, Heart Disease, Pain, Neurological Disorders and Infectious Diseases
Update Posted Online Today Shows 99 Programs Across 11 Therapeutic Areas, With 47 in Phase II and Significant Growth in Biologics
NEW YORK--Pfizer said today that it now has a total of 47 programs in its Phase II Research and Development pipeline, which is the largest Phase II cohort in its history and represents continued progress toward its target of tripling the companyâ€™s Phase III portfolio by 2009.
â€œThe growth of our Phase II cohort is encouraging progress toward meeting our target for our Phase III portfolio by 2009,â€ said Pfizerâ€™s Chairman and Chief Executive Officer Jeff Kindler. â€œWith the progress we are seeing in our pipeline -- as well as our efforts in reducing our attrition rates â€“ we are also continuing to target having a steady stream of new medicines from our internal R&D, four a year, starting in 2011. Our portfolio is very promising and focused on markets where we see substantial opportunities to meet unmet medical needs with innovative science and technology. We will continue to sharpen the focus and simplify the structure of our R&D organization so that we bring our pipeline forward to commercialization as rapidly as possible and enhance our productivity in all aspects of our clinical work.â€
The pipeline update, posted today at http://www.pfizer.com/pipeline, provides information on progress of candidates since the posting last December:
â€œThe continuing momentum in our pipeline and the progress we are making in advancing important new compounds are tangible evidence that the changes weâ€™ve made in our organization are having real impact where it matters most: the breadth and depth of our pipeline,â€ said John LaMattina, President of Pfizer Global Research and Development, who announced his plans to retire from the company earlier this year.
â€œIn the last eight months, we have advanced 27 programs, with the loss of just 13. Our progress is especially gratifying since we are continuing to make major structural and organizational changes while we pursue all of these opportunities. We are revising the allocation of our capital so that we target the areas of greatest medical and commercial promise, and I am confident that you will see Pfizer bring forward significant new therapies to fight cancer, cardiovascular disease, neurological disorders, infections and many other conditions. This performance is remarkable in a period of profound change and is a testament to the commitment and dedication of my colleagues in Pfizer Global Research & Development,â€ he added.
Research focus continues on areas of high medical need
Highlights of todayâ€™s update include new information on five of Pfizerâ€™s 11 therapeutic areas: 1) oncology; 2) cardiovascular, metabolic and endocrine disease; 3) pain; 4) the neuroscience portfolio; and 5) infectious diseases.
Oncology is a major focus of Pfizerâ€™s medical research. The company invests more than 20% of its development budget in this area with 20 active programs in immunotherapy, angiogenesis inhibition and signal transduction inhibition. The pipeline includes potential treatments across numerous tumor types, underscoring the companyâ€™s multidimensional approach to cancer treatment. The company now has compounds either in or nearing Phase III that, in total, address more than 70 percent of deaths due to various cancer types.
Pfizer continues to build on its traditional strengths in cardiovascular research and has expanded in metabolic and endocrine diseases. Apixaban, a compound being investigated for the prevention and treatment of a broad range of venous and arterial thrombotic conditions, is being jointly developed with Bristol-Myers Squibb. Phase II trials for thrombosis treatment have been completed. Phase III trials in venous thromboembolism prevention in patients undergoing total knee replacement surgery will seek to demonstrate superiority to enoxaparin, and Phase II trials are evaluating apixaban for acute coronary syndrome. Phase III trials are also underway to study apixaban for the prevention of stroke in patients with atrial fibrillation.
The updated pipeline shows eight candidates for pain, with an additional nine in the related area of inflammation. The company's scientists are now developing many innovative compounds aimed at novel, recently-discovered biological targets with the potential to alter, reduce or block the transmission of pain signals. For S,S-reboxetine (a selective norepinephrine reuptake inhibitor), Pfizer is encouraged by the data from a Phase II trial in patients with fibromyalgia. Phase II trials have progressed as monotherapy or in combination with Lyrica for post-herpetic neuralgia. A Phase II trial is being planned for painful diabetic neuropathy.
In neuroscience, Pfizer received approval during the period for Lyricaâ€™s fibromyalgia indication, an important line extension in the U.S. Lyrica is currently in Phase III testing for epilepsy monotherapy and Generalized Anxiety Disorder (GAD) in the U.S., as well as Phase II for restless leg syndrome. Geodon is another in-line Pfizer medicine with potential new indications: it is in Phase II for adjunctive bipolar depression and Phase III for bipolar relapse prevention.
In infectious diseases, Pfizer scientists are working on new treatments for diseases that have a devastating impact of many parts of the world, including malaria, hepatitis C and HIV/AIDS. Today we announced FDA approval for SelzentryTM (maraviroc), for the treatment of HIV in treatment-experienced patients. Maraviroc is also in Phase II testing for rheumatoid arthritis.
â€œWe will continue to update our pipeline so that investors, doctors, the scientific community, patients and their families can see how our research is advancing,â€ said Mr. Kindler. â€œThese updates are an important part of our commitment to transparency in all aspects of our operations, and we look forward to reporting on our continuing progress.â€
DISCLOSURE NOTICE: The information contained in this release is as of August 6, 2007. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about various products in development and potential additional indications for various in-line products, including their potential benefits, as well as targets with respect to the advancement of product candidates within the Companyâ€™s research and development pipeline, that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications that may be filed for such products in development and such additional indications for in-line products as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products and such additional indications; and competitive developments.
A further description of risks and uncertainties can be found in Pfizerâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.